2-(4-benzhydryl-piperazin-1-yl)-N,N-diphenyl-acetamide | 866562-65-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(4-benzhydryl-piperazin-1-yl)-N,N-diphenyl-acetamide
• 英文别名: 2-(4-(Diphenylmethyl)piperazinyl)-N,N-diphenylethanamide；2-(4-benzhydrylpiperazin-1-yl)-N,N-diphenylacetamide
• CAS: 866562-65-4
• 化学式: C₃₁H₃₁N₃O
• 分子量: 461.607
• InChiKey: QXNYWQVYZYCACA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.76
• 重原子数：
  35.0
• 可旋转键数：
  7.0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  26.79
• 氢给体数：
  0.0
• 氢受体数：
  3.0

反应信息

• 作为产物：
  描述：

  二苯甲基哌嗪 、 2-bromo-N,N-diphenylacetamide 在 碳酸氢钠 作用下， 以 乙酸乙酯 、 乙腈 为溶剂， 以84%的产率得到2-(4-benzhydryl-piperazin-1-yl)-N,N-diphenyl-acetamide
  参考文献：
  名称：

  Diarylamine derivatives as calcium channel blockers

  摘要：

  衍生自二芳基胺基哌嗪和氨基哌啶的化合物在治疗受钙离子通道活性介导的疾病方面具有用处。

  公开号：

  US20050227999A1

文献信息

• Indazole compounds, compositions thereof and methods of treatment therewith
  申请人：Bhagwat S. Shripad

  公开号：US20050009876A1

  公开（公告）日：2005-01-13

  This invention is generally directed to the use of Indazole Compounds for treating or preventing diseases associated with protein kinases, including tyrosine kinases, such as proliferative diseases, inflammatory diseases, abnormal angiogenesis and diseases related thereto, atherosclerosis, macular degeneration, diabetes, obesity, pain and others. The methods comprise the administration to a patient in need thereof of an effective amount of an indazole compound that inhibits, modulates or regulates tyrosine kinase signal transduction. Novel indazole compounds or pharmaceutically acceptable salt thereof are presented herein.

  这项发明通常涉及使用吲唑化合物来治疗或预防与蛋白激酶相关的疾病，包括酪氨酸激酶，诸如增殖性疾病、炎症性疾病、异常血管生成及其相关疾病、动脉硬化、黄斑变性、糖尿病、肥胖、疼痛等。这些方法包括向有需要的患者施用有效量的吲唑化合物，以抑制、调节或控制酪氨酸激酶信号转导。本文中提供了一种新型的吲唑化合物或其药用可接受的盐。
• Structure–activity relationships of diphenylpiperazine N-type calcium channel inhibitors
  作者：Hassan Pajouhesh、Zhong-Ping Feng、Yanbing Ding、Lingyun Zhang、Hossein Pajouhesh、Jerrie-Lynn Morrison、Francesco Belardetti、Elizabeth Tringham、Eric Simonson、Todd W. Vanderah、Frank Porreca、Gerald W. Zamponi、Lester A. Mitscher、Terrance P. Snutch

  DOI：10.1016/j.bmcl.2010.01.008

  日期：2010.2

  A novel series of compounds derived from the previously reported N-type calcium channel blocker NP118809 (1-(4-benzhydrylpiperazin-1-yl)-3,3-diphenylpropan-1-one) is described. Extensive SAR studies resulted in compounds with IC50 values in the range of 10-150 nM and selectivity over the L-type channels up to nearly 1200-fold. Orally administered compounds 5 and 21 exhibited both anti-allodynic and anti-hyperalgesic activity in the spinal nerve ligation model of neuropathic pain. (C) 2010 Elsevier Ltd. All rights reserved.
• Scaffold-based design and synthesis of potent N-type calcium channel blockers
  作者：Gerald W. Zamponi、Zhong-Ping Feng、Lingyun Zhang、Hossein Pajouhesh、Yanbing Ding、Francesco Belardetti、Hassan Pajouhesh、David Dolphin、Lester A. Mitscher、Terrance P. Snutch

  DOI：10.1016/j.bmcl.2009.09.008

  日期：2009.11

  The therapeutic agents flunarizine and lomerizine exhibit inhibitory activities against a variety of ion channels and neurotransmitter receptors. We have optimized their scaffolds to obtain more selective N-type calcium channel blockers. During this optimization, we discovered NP118809 and NP078585, two potent N-type calcium channel blockers which have good selectivity over L-type calcium channels. Upon intraperitoneal administration both compounds exhibit analgesic activity in a rodent model of inflammatory pain. NP118809 further exhibits a number of favorable preclinical characteristics as they relate to overall pharmacokinetics and minimal off-target activity including the hERG potassium channel. (C) 2009 Elsevier Ltd. All rights reserved.
• DIARYLAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS
  申请人：Neuromed Pharmaceuticals, Ltd.

  公开号：EP1745042A1

  公开（公告）日：2007-01-24
• [EN] DIARYLAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS<br/>[FR] DERIVES DE DIARYLAMINE UTILISES COMME BLOQUANTS DES CANAUX CALCIQUES
  申请人：NEUROMED TECH INC

  公开号：WO2005097779A1

  公开（公告）日：2005-10-20

  N-diarylaminoalkyl-substituted piperazine/4-aminopiperidine compounds of formula (1) are disclosed, wherein each of A and B is independently a 6-membered aromatic or nonaromatic, carbocyclic or heterocyclic moiety or is an aminoalkyl and wherein one and only one of A and B may be H or alkyl (1-8C) or wherein A and B together form an optionally substituted 6-membered aromatic of nonaromatic, carbocyclic or heterocyclic moiety; R1 is H or alkyl (1-8C), Z is N or CHNR2 wherein R2 is H or alkyl (1-8C), X is straight chain alkylene (1-4C) wherein optionally at least one carbon adjacent to a nitrogen is in the form of C=0; each R3 is an independent substituent; n=0-2; Ar is a six-membered aromatic or heteroaromatic ring; wherein each cyclic moiety included in A or B each Ar moiety in formula (1) may be substituted by one or more substituents. These compounds and salts or conjugated thereof are able to block N-type and T-type calcium channels and are useful for treating conditions mediated by calcium ion channel activity such as chronic pain.